Your Article Summary
See Latest ArticlesThe safety profile of ciclesonide in the treatment of persistent asthma
Allergy and Asthma Proceedings, 07/01/09
Craig T - There was no clinically relevant effect of CIC treatment on growth in children with mild asthma compared with placebo. The favorable safety profile of CIC may allay patient and physician concern regarding ICS when using this agent. Guideline-recommended use of ICS medications may help optimize treatment outcomes in asthma.
Related Articles
Clinical importance of identifying immunoglobulin E-mediated disease in patients with Asthma
Clinical Cornerstone, 10/01/09
Relevance Score: 96%
Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma
Osteoporosis International, 10/13/09
Relevance Score: 95%
The Saudi Initiative for asthma
Annals of Thoracic Medicine, 10/13/09
Relevance Score: 95%
Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study
Journal of Allergy and Clinical Immunology, 10/09/09
Relevance Score: 95%
Identification of Asthma Phenotypes using Cluster Analysis in the Severe Asthma Research Program
American Journal of Respiratory and Critical Care Medicine, 11/09/09
Relevance Score: 94%
Today in Cardiovascular/Pulm...keeping you current
Receive free subspecialty "5-minute updates" via email
CD4+CD25+ regulatory T cells attenuate hypersensitivity pneumonitis by suppressing IFN-[gamma] production by CD4+ and CD8+ T cells
Journal of Leukocyte Biology, 12/17/09
Differential requirements for IL-4/STAT6 signalling in CD4 T-cell fate determination and Th2-immune effector responses
Immunology & Cell Biology, 12/17/09
Novel Role for Aldose Reductase in Mediating Acute Inflammatory Responses in the Lung
Journal of Immunology, 12/16/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Efficacy and safety of azelastine 0.15% nasal spray and azelastine 0.10% nasal spray in patients with seasonal allergic rhinitis
Allergy and Asthma Proceedings, 12/17/09
Anti-TNF-[alpha] therapy with infliximab in spondyloarthritides
Expert Review of Clinical Immunology, 12/17/09
Immunosuppression Using the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus: Pilot Study Shows Significant Cognitive and Affective Improvement
Transplantation Proceedings, 12/17/09